QTC intervals can be assessed with the AliveCor heart monitor in patients on dofetilide for atrial fibrillation☆
References (3)
Tikosyn (dofetilide) home
There are more references available in the full text version of this article.
Cited by (70)
Artificial intelligence–enabled classification of hypertrophic heart diseases using electrocardiograms
2023, Cardiovascular Digital Health JournalCan we predict sudden cardiac death?
2023, Bulletin de l'Academie Nationale de MedecineThe Role of Contemporary Wearable and Handheld Devices in the Diagnosis and Management of Cardiac Arrhythmias
2022, Heart Lung and CirculationUse of Smartphones and Wearables for Arrhythmia Monitoring
2021, Cardiac Electrophysiology ClinicsRemote Monitoring of the QT Interval and Emerging Indications for Arrhythmia Prevention
2021, Cardiac Electrophysiology ClinicsCitation Excerpt :These 3 studies concluded a good accuracy in the determination of QTc prolongation; however, 2 larger studies did not fully reproduce this positive result.20,21 In 2015 Chung and colleagues17 explored the possibility of using the AliveCor heart monitor to oversee the QTc changes in just 5 patients with atrial fibrillation taking dofetilide. They compared an AliveCor tracing for each patient with an ECG performed at approximately the same time that day.
Usefulness of Mobile Electrocardiographic Devices to Reduce Urgent Healthcare Visits
2021, American Journal of Cardiology
- ☆
This report contains data presented as an oral abstract at the 2014 American Heart Association Scientific Sessions in Chicago, Illinois.
Copyright © 2015 Elsevier Inc. All rights reserved.